Skip to main content
. Author manuscript; available in PMC: 2013 Apr 8.
Published in final edited form as: Cell Cycle. 2009 Jul 23;8(14):2266–2280. doi: 10.4161/cc.8.14.9101

Figure 6.

Figure 6

VEGFR-3 increases motility of breast cancer cells. (A) Motility of MCF7-VEGFR-3 cells relative to MCF7-pcDNA3 cells (folds increase, p < 0.05). (B) MCF7-VEGFR-3 cells treated with 10 nM VEGFR-3-specific siRNA for 48 h and motility compared to parental and Control siRNA treated MCF7-VEGFR-3 (fold decrease, **p < 0.001). (C) BT474 cells treated with 10 nM VEGFR-3-specific siRNA for 48 h and motility compared to parental and Control siRNA treated BT474 (fold decrease, *p < 0.05). (D) Motility of BT474 shRNA stable clones. (E) Motility of MCF7-VEGFR-3 shRNA stable clones.